Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 5 mg - wafer - excipient ingredients: mannitol; sodium methyl hydroxybenzoate; sodium propyl hydroxybenzoate; aspartame; gelatin - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 10 mg - injection, powder for - excipient ingredients: tartaric acid; lactose monohydrate - zyprexa im is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia and related psychoses and in patients with acute mania associated with bipolar i disorder, when oral therapy is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nafarelin, quantity: 2 mg/ml - spray, solution - excipient ingredients: benzalkonium chloride; sorbitol; glacial acetic acid; hydrochloric acid; purified water; sodium hydroxide - indications as at 31 august 1995. synarel is indicated for the hormonal management of visually proven endometriosis, including pain relief and reduction of endometriotic lesions and for use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: hypromellose; triethyl citrate; indigo carmine; purified talc; sodium lauryl sulfate; gelatin; iron oxide yellow; sucrose; hypromellose acetate succinate; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; povidone; tert-butyl alcohol; sodium hydroxide; maize starch - cymbalta is indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - duloxetine hydrochloride, quantity: 33.7 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: sodium lauryl sulfate; sucrose; triethyl citrate; titanium dioxide; gelatin; indigo carmine; hypromellose; purified talc; hypromellose acetate succinate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; iron oxide yellow; shellac; ethanol absolute; iron oxide black; potassium hydroxide; ammonia - cymbalta is indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - duloxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - duloxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 200 iu/ml - injection, solution - excipient ingredients: glycerol; zinc oxide; trometamol; water for injections; hydrochloric acid; sodium hydroxide; metacresol - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; glycerol; phenol; water for injections; dibasic sodium phosphate heptahydrate; metacresol; zinc oxide; sodium hydroxide; protamine sulfate - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.